Stay updated on OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page.

Latest updates to the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedRevision changed from v3.6.5 to v3.6.6, indicating a new release of the page’s content. This update signals administrative or formatting improvements and does not modify the study details.SummaryDifference0.1%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedThe revision label on the page updated from v3.6.4 to v3.6.5, indicating a small platform update rather than a substantive content change.SummaryDifference0.0%

- Check51 days agoChange DetectedRevision: v3.6.4 was added and the previous Revision: v3.6.3 was removed, indicating a small update to the page's revision history.SummaryDifference0.0%

- Check72 days agoChange DetectedThe page revision changed from v3.6.2 to v3.6.3. This appears to be a minor maintenance/version-control update rather than a substantive change to the study information or user-facing content.SummaryDifference0.0%

- Check80 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, indicating a backend release update. No visible changes to study details or page content are evident.SummaryDifference0.0%

- Check94 days agoChange Detected- Added user guidance sections: How to Read a Study Record, Common Questions, How to Join a Study, and a recruitment status note: 'No longer looking for participants'. - Updated revision/version label to v3.6.0 and adjusted the Intervention/Treatment heading formatting (from 'Intervention / Treatment').SummaryDifference0.4%

Stay in the know with updates to OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page.